Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0IZ7T
|
|||
Former ID |
DIB010733
|
|||
Drug Name |
YM-17E
|
|||
Synonyms |
YM-17E; YM17E; 124884-99-7; AC1L46WN; SCHEMBL6340546; DTXSID80154515; 1-cycloheptyl-1-[[3-[[cycloheptyl-[(4-dimethylaminophenyl)carbamoyl]amino]methyl]phenyl]methyl]-3-(4-dimethylaminophenyl)urea dihydrochloride
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.5] | Discontinued in Phase 1 | [1] | |
Company |
Yamanouchi Pharmaceutical Co Ltd
|
|||
Structure |
Download2D MOL |
|||
Formula |
C40H58Cl2N6O2
|
|||
Canonical SMILES |
CN(C)C1=CC=C(C=C1)NC(=O)N(CC2=CC(=CC=C2)CN(C3CCCCCC3)C(=O)NC4=CC=C(C=C4)N(C)C)C5CCCCCC5.Cl.Cl
|
|||
InChI |
1S/C40H56N6O2.2ClH/c1-43(2)35-24-20-33(21-25-35)41-39(47)45(37-16-9-5-6-10-17-37)29-31-14-13-15-32(28-31)30-46(38-18-11-7-8-12-19-38)40(48)42-34-22-26-36(27-23-34)44(3)4;;/h13-15,20-28,37-38H,5-12,16-19,29-30H2,1-4H3,(H,41,47)(H,42,48);2*1H
|
|||
InChIKey |
AKJWTZIUYIFCCS-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 124884-99-7
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Liver carboxylesterase (CES1) | Target Info | Modulator | [2] |
KEGG Pathway | Drug metabolism - other enzymes | |||
Metabolic pathways | ||||
Pathway Interaction Database | E2F transcription factor network | |||
WikiPathways | NRF2 pathway | |||
Nuclear Receptors Meta-Pathway | ||||
Heroin metabolism | ||||
Irinotecan Pathway | ||||
Fluoropyrimidine Activity | ||||
Phase I biotransformations, non P450 |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002618) | |||
REF 2 | Pharmacological properties of YM17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs. Jpn J Pharmacol. 1997 Jan;73(1):41-50. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.